Media

Strongbridge Biopharma plc Announces Presentation at Bio€quity Europe 2016

Nordic Nanovector announces first patient enrolled in Arm 3 of expanded Phase 1/2 study of Betalutin® in NHL patients

WILSON THERAPEUTICS ANNOUNCES INITIAL PUBLIC OFFERING ON NASDAQ STOCKHOLM

Interim Report January-March 2016

Nexstim Plc announces the change of CEO

SAVE THE DATE – NORDIC NANOVECTOR CAPITAL MARKETS DAY

Onxeo Final Data from Mechanistic Livatag® Study Show Preferential Affinity for Liver, Support Use as Advanced HCC Treatment

Cerenis Therapeutics announces the publication of an initiation of coverage report by PORTZAMPARC, within the framework of the share’s market coverage

Nordic Nanovector ASA: Betalutin® continues to show promising efficacy and increasing Duration of Response (DoR)